- Home
- IBIO vs CLNN Comparison
IBIO vs CLNN Comparison
Compare IBIO & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | CLNN |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 67.5M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBIO | CLNN |
|---|---|---|
| Price | $1.43 | $4.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.75 | ★ $33.75 |
| AVG Volume (30 Days) | ★ 561.5K | 78.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $3.88 |
| 52 Week High | $3.82 | $13.50 |
Technical Indicators
Market Signals| Indicator | IBIO | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 29.38 |
| Support Level | $1.29 | $3.88 |
| Resistance Level | $2.10 | $4.60 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 56.00 | 13.01 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.